SCHEMBL10090239

SCHEMBL10090239

CCc1ccc(CCOc2ccc(Br)cc2/C=C2\SC(=S)NC2=O)nc1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PTP4A3 O75365 8/20 0.60
▸ HPGD P15428 1/20 0.60
▸ PTPN1 P18031 4/20 0.50
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ MYC P01106 1/20 0.47
▸ MAX P61244 1/20 0.47
▸ PDE4B Q07343 2/20 0.45
▸ PDE3A Q14432 2/20 0.45
▸ GSK3B P49841 2/20 0.45
▸ PTPN2 P17706 1/20 0.44
▸ PTPN6 P29350 1/20 0.44
▸ PPARG P37231 1/20 0.44
▸ DYRK1A Q13627 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2066610 1.00 PTP4A3 (0.60) PTP4A3HPGDPTPN1NPC1RAB9A
SCHEMBL2065524 0.83 PTP4A3 (0.67) PTP4A3HPGDPTPN1GSK3B
SCHEMBL2065526 0.83 PTP4A3 (0.67) PTP4A3HPGDPTPN1GSK3B
SCHEMBL10090242 0.83 PTP4A3 (0.67) PTP4A3HPGDPTPN1GSK3B
SCHEMBL2065600 0.80 PTP4A3 (0.82) PTP4A3HPGDPTPN1GSK3B
SCHEMBL2065602 0.80 PTP4A3 (0.82) PTP4A3HPGDPTPN1GSK3B
SCHEMBL10090190 0.80 PTP4A3 (0.82) PTP4A3HPGDPTPN1GSK3B
SCHEMBL885397 0.79 PTP4A3 (0.87) PTP4A3PTPN1PTPN2PTPN6PPARG
SCHEMBL10090205 0.79 PTP4A3 (0.87) PTP4A3PTPN1PTPN2PTPN6PPARG
SCHEMBL10090151 0.79 PTP4A3 (0.69) PTP4A3PTPN1PDE4BPDE3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same PTPRR, PTPRG, PTPRS PTP4A3 28/4885HPGD 2629/4885PTPN1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback